4 results about "Rheumatic disease" patented technology

This utility model discloses a production device for a gel used in rheumatism, relating to the field of gel production technology for rheumatism. It includes a base and a mixing tank. A fixing frame is provided on the upper outer surface of the base, and a shaking frame is provided in the middle of the fixing frame. A first drive motor is fixedly installed on one outer surface of the fixing frame, and a tank lid is provided on the upper outer surface of the mixing tank. In this rheumatism gel production device, the shaking frame is connected to the mixing tank via an internal vibration motor. A second drive motor drives a shaft to stir the material. During stirring, the vibration motor is activated, simultaneously vibrating the mixing tank and a movable block. This prevents material from adhering to the inner wall of the mixing tank. When the movable block is vibrated, it shakes via a limit spring, indirectly causing the mixing tank to shake, thus improving the mixing effect and efficiency of the material inside the mixing tank.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

The present disclosure provides a composition comprising primed extracellular vesicles and a biologically or pharmaceutically acceptable carrier, wherein the primed extracellular vesicles comprise an upregulated miRNA, and a fold change of the upregulated miRNA of the primed extracellular vesicles compared to miRNA of naturally occurring extracellular vesicles is greater than 1. The present disclosure further provides a method for preventing, treating, or ameliorating a gynecological or a rheumatological disorder comprising administering the composition of the present disclosure to a subject in need thereof. The present disclosure also provides a method for producing the composition. The method comprises cultivating a stem cell in a culture medium containing a Polygonum multiflorum Thunb extract and resveratrol to obtain a cell culture.

The application relates to an engineered exosome and a preparation method and application thereof, wherein the engineered exosome comprises a natural exosome, a photosensitizer and miR451a loaded in the natural exosome, and an anti-FAP alpha antibody or an antibody fragment loaded on the surface of the natural exosome; the anti-FAP alpha antibody is used for guiding the target receptor cell of the engineered exosome to be combined; the photosensitizer and the miR451a participate in the occurrence of ferroptosis of the target receptor cell under the action of photodynamic effect; and the target receptor cell is an activated fibroblast-like synoviocyte in rheumatic lesions. The application has the beneficial effects of providing a synergistic scheme of "biological carrier + physical stimulation" for RA treatment and having the treatment characteristics of high efficiency, low toxicity and high targeting.